Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  3SBio Inc. (ADR)    YFK

 SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CNY)
Sales 2016 2 881 M
EBIT 2016 882 M
Net income 2016 717 M
Debt 2016 1 775 M
Yield 2016 0,43%
Sales 2017 3 654 M
EBIT 2017 1 129 M
Net income 2017 957 M
Debt 2017 939 M
Yield 2017 0,55%
P/E ratio 2016 28,05
P/E ratio 2017 21,28
EV / Sales2016 7,64x
EV / Sales2017 5,79x
Capitalization 20 223 M
More Financials
Company
3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products.It is used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.The company... 
Sector
Pharmaceuticals
Calendar
03/21Earnings Release
More about the company
Surperformance© ratings of 3SBio Inc. (ADR)
Trading Rating : Investor Rating :
More Ratings
Latest news on 3SBIO INC. (ADR)
02/24 3SBIO : says 3 products listed in 2017 National Drug List
2016 3SBIO : granted exclusive license of diabetes drugs
2016 3SBIO : AstraZeneca Ink Licensing Agreement
2016 3SBIO : gets nod for colorectal cancer drug clinical trial
2016 3SBIO INC. : (01530) says ITP drug get clinical trial approval
2016 3SBIO INC. : (01530) withdraws breast cancer drug application
2016 3SBIO : PEG-irinotecan Wins IND Approval From China FDA
2016 3SBIO : Bought CNY3.9bn Shares in CPGJ
2016 3SBIO : adds stake in CP Guojian Pharma at Rmb3.9bn
2016DJChinese Drugmaker Plans up to $3 Billion Hong Kong IPO
More news
Sector news : Biopharmaceuticals
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
02/24 Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
More sector news : Biopharmaceuticals
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 8,73  CNY
Spread / Average Target 9,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jing Lou Chairman, President & Chief Executive Officer
Wei hong Xiao Chief Operating Officer
Bo Tan Chief Financial Officer & Executive Director
Zhenping Zhu Chief Scientific Officer, President-R&D
Dong Mei Su Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
3SBIO INC. (ADR)0.00%2 946
BIOGEN INC8.96%61 574
CSL LIMITED17.26%41 358
ALEXION PHARMACEUTICAL..6.61%29 546
BIOMARIN PHARMACEUTICA..7.79%15 051
GRIFOLS SA10.28%13 922
More Results